<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05022693</url>
  </required_header>
  <id_info>
    <org_study_id>BIO89-100-111</org_study_id>
    <nct_id>NCT05022693</nct_id>
  </id_info>
  <brief_title>PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis</brief_title>
  <official_title>An Open-Label, Single-Dose Pharmacokinetic Study of Liquid Subcutaneous Formulation of BIO89-100 in Subjects With Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>89bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>89bio, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-dose study to evaluate the PK profile of the liquid SC&#xD;
      formulation of BIO89-100 in approximately 8 male and female subjects with NASH with&#xD;
      compensated cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label, single dose, PK study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK Profile of liquid formulation of BIO89-100</measure>
    <time_frame>22 days</time_frame>
    <description>Determine maximum observed serum drug concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Profile of liquid formulation of BIO89-100</measure>
    <time_frame>22 days</time_frame>
    <description>Area under the serum drug concentration-by-time curve from time 0 to the time of the last quantifiable drug concentration (AUC0-t)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety and tolerability of the BIO89-100 liquid formulation</measure>
    <time_frame>22 days</time_frame>
    <description>Frequency and severity of adverse events (AEs) and serious adverse events (SAEs)&#xD;
Number of subjects who discontinued due to AEs and due to related AEs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>BIO89-100 30 mg, Open Lable, Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIO89-100</intervention_name>
    <description>Subcutaneous Injections</description>
    <arm_group_label>BIO89-100 30 mg, Open Lable, Single Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Age 21 to 65&#xD;
&#xD;
          -  Diagnosis of NASH with compensated cirrhosis by a hepatologist based on Liver Forum&#xD;
             criteria.&#xD;
&#xD;
          -  Model for End-Stage Liver Disease (MELD) score &lt; 12.&#xD;
&#xD;
          -  Child-Turcotte-Pugh (CTP) score &lt; 7 (Class A).&#xD;
&#xD;
          -  Fibrosis stage F4 by FibroScan.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of hepatic cirrhosis decompensation, OR overt hepatic encephalopathy OR signs&#xD;
             of hepatic cirrhosis decompensation.&#xD;
&#xD;
          -  Prior transjugular intrahepatic portosystemic (TIPS) shunt procedure.&#xD;
&#xD;
          -  known condition other than cirrhosis that may possibly interfere with drug absorption,&#xD;
             distribution, metabolism, or excretion.&#xD;
&#xD;
          -  Significant alcohol consumption for a period of more than 3 consecutive months within&#xD;
             1 year prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trial Lead</last_name>
    <phone>510-378-8824</phone>
    <email>harpreet.nagra@89bio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>89bio Clinical Study Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>89bio Clinical Study Site</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

